<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02354534</url>
  </required_header>
  <id_info>
    <org_study_id>J1498</org_study_id>
    <secondary_id>IRB00045376</secondary_id>
    <nct_id>NCT02354534</nct_id>
  </id_info>
  <brief_title>Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)</brief_title>
  <official_title>A Phase I Study of Intravaginally Administered Artesunate In Women With High Grade Cervical Intraepithelial Neoplasia (CIN2/3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Frantz Viral Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I research protocol is designed to assess immunogenicity and clinical endpoints in
      patients with HPV16 CIN2/3. The protocol tests the use of artesunate in suppository
      formulation applied intravaginally in patients with cervical dysplasia (CIN2/3).

      The primary endpoint is to determine and evaluate the safety, tolerability, and feasibility
      of intravaginal administration of artesunate in health women with CIN2/3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I open-label dose escalation study of intravaginal artesunate, formulated in
      suppositories, in adult females with biopsy-confirmed CIN2/3. Thirty (30) subjects will
      undergo up to a total of three cycles of intravaginal artesunate. The first cycle will be
      initiated on Day 0, the second at Week 4, and the third and final cycle at week 8.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">November 6, 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of Artesunate vaginal suppositories in women with cervical intraepithelial neoplasia (CIN2/3) as determined by number of participants with serious adverse events</measure>
    <time_frame>15 weeks</time_frame>
    <description>Number of participants with related serious adverse events or dose limiting toxicities assessed using CTCAE4.0 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral clearance of HPV</measure>
    <time_frame>41 weeks</time_frame>
    <description>Number of participants whose HPV genotypes present at study entry become undetectable without surgical intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic regression of CIN2/3</measure>
    <time_frame>41 weeks</time_frame>
    <description>Number of participants with histologic regression from CIN2/3 to CIN1 or less, as assessed by colposcopically-directed biopsies</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Cervical Intraepithelial Neoplasia Grade 2/3</condition>
  <condition>High-risk HPV (Any Strain)</condition>
  <arm_group>
    <arm_group_label>50 mg Artesunate suppositories, 1 cycle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg Artesunate suppositories, 1 cycle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg Artesunate suppositories,2 cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled in this cohort will receive 2 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg Artesunate suppositories,3 cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled in this cohort will receive 3 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate Suppositories</intervention_name>
    <arm_group_label>200 mg Artesunate suppositories, 1 cycle</arm_group_label>
    <arm_group_label>200 mg Artesunate suppositories,2 cycles</arm_group_label>
    <arm_group_label>200 mg Artesunate suppositories,3 cycles</arm_group_label>
    <arm_group_label>50 mg Artesunate suppositories, 1 cycle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years

          -  Capable of informed consent

          -  HPV-positive by DNA test

          -  Histologically confirmed CIN2, CIN3, or CIN2/3

          -  Body weight ≥ 50 kg

          -  Immune competent

        Exclusion Criteria:

          -  Pregnant and nursing women

          -  HIV seropositive

          -  Active autoimmune disease

          -  Taking immunosuppressive medication

          -  Evidence of concurrent adenocarcinoma in situ

          -  Concurrent malignancy except for nonmelanoma skin lesions
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia L Trimble, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Outpatient Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <last_update_submitted>May 24, 2019</last_update_submitted>
  <last_update_submitted_qc>May 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical dysplasia</keyword>
  <keyword>HPV</keyword>
  <keyword>Treatment</keyword>
  <keyword>preinvasive</keyword>
  <keyword>cervix</keyword>
  <keyword>vaginal suppository</keyword>
  <keyword>Cornelia Trimble</keyword>
  <keyword>abnormal pap</keyword>
  <keyword>CIN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

